Ipsen ((GB:0MH6)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
In a significant update for the pharmaceutical industry, Ipsen is conducting an observational study titled ‘REPLICA: Real Patient Life Treatment With Cabozantinib in Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic RCC.’ The study aims to describe the real-life use of Cabometyx® alone or with nivolumab in treating advanced or metastatic renal cell carcinoma (RCC) in Belgium. This research is crucial as it provides insights into the effectiveness of these treatments in real-world settings.
The study focuses on Cabometyx®, a drug used either on its own or in combination with nivolumab, an immunotherapy agent. These treatments are intended to manage advanced RCC, offering potential new avenues for patient care.
This is an observational cohort study with a prospective time perspective, meaning it follows patients over time to observe outcomes. The study does not involve random allocation or masking, focusing instead on real-life treatment patterns and outcomes.
The study began on September 25, 2019, and is currently recruiting participants. The most recent update was submitted on August 28, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates on its findings.
The ongoing study could influence Ipsen’s stock performance positively by demonstrating the effectiveness of its treatments in real-world settings, potentially boosting investor confidence. It also positions Ipsen competitively within the pharmaceutical industry, particularly in the oncology sector.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.